JP Morgan's survey of endocrinologists finds strong awareness of Crinetics' atumelnant, with positive efficacy impressions.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on KalVista Pharmaceuticals (KALV – Research ...

Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.

Fintel reports that on March 25, 2025, Stifel initiated coverage of Crinetics Pharmaceuticals (NasdaqGS:CRNX) with a Buy recommendation. Analyst Price Forecast Suggests 114.68% Upside As of March 19, ...

Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Crinetics Pharmaceuticals, Inc. announced the grant of stock options and restricted stock units (RSUs) to new employees on March 10, 2025, as part of their 2021 Employment Inducement Incentive ...

SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the Board of Directors granted ...

SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the Board of Directors granted ...

Crinetics Pharmaceuticals, Inc. SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of ...

We are thrilled to share the significant progress and strategic milestones NLS Pharmaceutics has achieved, positioning our company for a transformative future in the biotechnology sector.